Insulin-like growth factor binding protein-1 and fetal fibronectin dual detection system and its application and kit
Through specific treatment fluids and assembly steps, the detection system of insulin-like growth factor binding protein-1 and fetal fibronectin is improved, solving the problem of low sensitivity and specificity in the prior art, and achieving high specificity and strong repetition detection effect of sexual and long-term stability.
Patent Information
- Application Number
- CN202411126355.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-16
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-08-16
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The invention belongs to the field of immunoassay, and specifically relates to an insulin-like growth factor binding protein-1 and fetal fibronectin dual detection system and an application and a kit thereof. Background Art
[0002] Premature birth refers to the situation where the baby is born after 28 weeks of pregnancy but before 37 weeks. The newborns born at this time are called premature babies. Premature birth is a common complication of delivery in clinical practice. The organs of premature babies born at this time are not fully developed. The smaller the gestational age at birth and the lighter the weight, the worse the prognosis. Premature birth accounts for 5% to 15% of the total number of births and is the leading cause of death in premature babies. There are many causes of premature birth, and its mechanism is relatively complex. Accurate prediction of premature birth is a difficult point in clinical diagnosis and treatment.
[0003] The most consensus predictors of preterm birth are measurements of cervical length, fetal fibronectin, and insulin-like growth factor binding protein-1.
[0004] Fetal connexin is a glycoprotein that can be detected in the vagina and secretions because the connection between the fetal membrane and the chorion is not closed. In normal pregnancy, fetal connexin can only be detected before 22 weeks of pregnancy. From the 22nd week to before delivery, due to the closure of the fetal membrane and the chorion, fetal connexin should be negative. Studies have shown that the clinical significance of fetal connexin determination lies in its negative predictive value. For patients with negative fetal connexin qualitative tests (concentration <50ng / mL), more than 90% of patients can continue to maintain pregnancy for more than 7 days; while for patients with positive test results (concentration ≥50ng / mL), only less than 30% of them will give birth within 7 to 10 days. Therefore, for the detection of fetal connexin in cervical secretions, a large number of studies have shown that its negative results are more predictive of not having premature birth in the short term. Some studies have also suggested that its prediction results have stronger predictive ability for early pregnancy (24-29 weeks) than late pregnancy, and stronger predictive ability for short-term prediction (7-14 days). Therefore, in clinical practice, unnecessary intervention measures can be reduced for pregnant women with negative fetal connexin. However, the positive predictive value of fetal connexin cannot 100% predict the occurrence of preterm birth, which reduces its specificity for predicting preterm birth.
[0005] Insulin-like growth factor binding protein-1 (IGFBP-1) is mainly present in amniotic fluid and is a marker protein in amniotic fluid during pregnancy. When the membranes rupture, the amniotic fluid leaks from the rupture of the membranes into the cervix and vagina, and the IGFBP-1 contained in it becomes a marker for the diagnosis of premature rupture of membranes. Currently, the most accurate method for detecting premature rupture of membranes is to detect the presence of insulin-like growth factor binding protein-1, with an accuracy rate of up to 90%. GFBP-1 ≥ 25ng / mL is judged as positive, and <25ng / mL is judged as negative.
[0006] Insulin-like growth factor binding protein-1 and fetal fibronectin are both substances released into the vagina of pregnant women when the uterus contracts and the placenta and decidua peel off. When the above two substances in the vagina of pregnant women are abnormally elevated, the occurrence of premature birth and premature rupture of the uterus can be predicted. Colloidal gold detection of insulin-like growth factor binding protein-1 and fetal fibronectin is of great value in medical diagnosis, but there are still problems with low sensitivity and specificity; the stability and repeatability of colloidal gold test kits also need to be improved. Summary of the invention
[0007] In order to solve the above problems, the present invention provides an insulin-like growth factor binding protein-1 and fetal fibronectin dual detection system, which is used to detect insulin-like growth factor binding protein-1 and fetal fibronectin in vaginal secretions. The method has strong specificity, strong repeatability, high accuracy and good long-term stability.
[0008] In one aspect, the present invention provides a dual detection system of insulin-like growth factor binding protein-1 and fetal fibronectin, the detection system comprising a sample pad, an immunocolloidal gold pad, a nitrocellulose membrane and absorbent paper;
[0009] The sample pad is treated with treatment solution A, and the formula of the treatment solution A can be: 10-20mM PBS buffer, 2%-5%m / V PEG6000, 1%-2%m / V Tween-20, 1%-2%m / V sodium citrate, 2%-4%m / V trehalose, 3%-5%m / V BSA, 0.3%-0.5%m / V PC-950, pH 7-8;
[0010] The immune colloidal gold pad is treated with treatment solution B, and the formula of the treatment solution B can be: 5-10mM PBS buffer, 0.1%-0.3%m / V PEG6000, 0.1%0.5%m / V Tween-20, 1%-3%m / V KCl, 2%-5%m / V trehalose, 0.5%-1.5%m / V mannitol, 1%-2%m / V BSA, 0.1%-0.4%m / V PC-950, pH 7-7.8.
[0011] In some embodiments, the treatment solution A may be formulated as follows: 20 mM PBS buffer, 2% m / V PEG6000, 1% m / V Tween-20, 2% m / V sodium citrate, 4% m / V trehalose, 3% m / V BSA, 0.3% m / V PC-950, pH 8;
[0012] The formula of the treatment solution B can be: 5mM PBS buffer, 0.1%m / V PEG6000, 0.5%m / V VTween-20, 1%m / V KCl, 2%m / V trehalose, 1.5%m / V mannitol, 1%m / V BSA, 0.1%m / V PC-950, pH 7.
[0013] In some other embodiments, the formula of the treatment solution A can be: 10 mM PBS buffer, 5% m / V PEG6000, 2% m / V Tween-20, 1% m / V sodium citrate, 2% m / V trehalose, 5% m / V BSA, 0.5% m / V PC-950, pH 7;
[0014] The formula of the treatment solution B can be: 10mM PBS buffer, 0.3%m / V PEG6000, 0.1%m / V Tween-20, 3%m / V KCl, 5%m / V trehalose, 0.5%m / V mannitol, 2%m / V BSA, 0.4%m / V PC-950, pH 7.8.
[0015] Specifically, the sample pad and the immunocolloidal gold pad may be made of glass cellulose membrane, polyester membrane or non-woven fabric.
[0016] Preferably, the sample pad and the immunocolloidal gold pad may be made of glass cellulose membrane.
[0017] In another aspect, the present invention provides a method for preparing the aforementioned insulin-like growth factor binding protein-1 and fetal fibronectin dual detection system, wherein the method comprises the following steps:
[0018] S1. Preparation of sample pad: soak the glass cellulose membrane in the aforementioned treatment solution A, dry it and set it aside;
[0019] S2. Preparation of immunocolloidal gold pad: soak the glass cellulose membrane in the aforementioned treatment solution B, dry it, spray it with the gold-labeled antibody mixed solution, dry it again and set it aside;
[0020] S3. Preparation of nitrocellulose membrane: coating the test line and quality control line on the nitrocellulose membrane;
[0021] S4. Assemble the reagent strip: assemble in the order of sample pad - immune colloidal gold pad - nitrocellulose membrane - absorbent paper;
[0022] Specifically, the immersion time in the treatment solution A described in step S1 is 8-15 minutes; the immersion time in the treatment solution B described in step S2 is 5-10 minutes.
[0023] Preferably, the immersion time in the treatment liquid A described in step S1 is 10 minutes; and the immersion time in the treatment liquid B described in step S2 is 7 minutes.
[0024] Specifically, the drying temperature of step S1 and step S2 may be 35-45°C.
[0025] Preferably, the drying temperature of step S1 and step S2 may be 40°C.
[0026] Specifically, the gold-labeled antibody mixed solution described in step S2 includes a gold-labeled antibody solution of insulin-like growth factor binding protein-1 antibody 1 and a gold-labeled antibody solution of fetal fibronectin antibody a.
[0027] More specifically, the preparation method of the gold-labeled antibody solution of the insulin-like growth factor binding protein-1 antibody 1 is as follows:
[0028] (1) Add sodium citrate to a boiling HAuCl4 aqueous solution, heat and stir, and cool to obtain a colloidal gold solution;
[0029] (2) Add K2CO3 solution to (1), mix well and set aside;
[0030] (3) adding insulin-like growth factor binding protein-1 antibody 1 to (2), stirring evenly and letting stand;
[0031] (4) Add blocking solution to (3), stir, let stand, centrifuge, and re-dissolve to obtain insulin-like growth factor binding protein-1 gold-labeled antibody solution.
[0032] More specifically, the blocking solution described in (4) includes BSA and PEG-20000.
[0033] More specifically, the solution for reconstitution described in (4) includes BSA.
[0034] More specifically, the preparation method of the gold-labeled antibody solution of fetal fibronectin antibody a is as follows:
[0035] (1) Add sodium citrate to a boiling HAuCl4 aqueous solution, heat and stir, and cool to obtain a colloidal gold solution;
[0036] (2) Add K2CO3 solution to (1), mix well and set aside;
[0037] (3) Add fetal fibronectin antibody a to (2), stir evenly and let stand;
[0038] (4) Add blocking solution to (3), stir, and allow to stand; centrifuge, and re-dissolve to obtain a fetal fibronectin antibody a gold-labeled antibody solution.
[0039] More specifically, the blocking solution described in (4) includes BSA and PEG-20000.
[0040] More specifically, the solution for reconstitution described in (4) includes BSA.
[0041] Specifically, the T1 detection line in step S3 is coated with insulin-like growth factor binding protein-1 antibody 2; the T2 detection line is coated with fetal fibronectin antibody b; and the quality control line is coated with IgG antibody.
[0042] Preferably, the IgG antibody is goat anti-mouse IgG.
[0043] In yet another aspect, the present invention provides the use of the aforementioned insulin-like growth factor binding protein-1 and fetal fibronectin dual detection system or method in the preparation of a kit for the dual detection of insulin-like growth factor binding protein-1 and fetal fibronectin.
[0044] In yet another aspect, the present invention provides a kit for dual detection of insulin-like growth factor binding protein-1 and fetal fibronectin, the kit comprising the aforementioned dual detection system of insulin-like growth factor binding protein-1 and fetal fibronectin.
[0045] Specifically, the kit also includes a sample preservation reagent.
[0046] Specifically, the sample is cervical secretions or vaginal secretions.
[0047] Preferably, the sample is vaginal secretions.
[0048] The technical effect achieved by the present invention is as follows: The detection principle of the insulin-like growth factor binding protein-1 and fetal fibronectin dual detection system of the present invention is as follows: the insulin-like growth factor binding protein-1 and fetal fibronectin in the cervical secretions dripped into the sample pad reach the immune colloidal gold pad and respectively form a complex with the insulin-like growth factor binding protein-1 antibody 1 and fetal fibronectin antibody a pre-coated on the surface of the colloidal gold particles in the reagent strip, and the complex migrates to the detection line and the quality control line on the nitrocellulose membrane through capillary action, and is captured by the insulin-like growth factor binding protein-1 antibody 2 and fetal fibronectin antibody b pre-coated on the membrane, and a red strip of corresponding concentration is displayed at the corresponding T line position according to the content of the insulin-like growth factor binding protein-1 and fetal fibronectin in the sample; Regardless of whether insulin-like growth factor binding protein-1 and fetal fibronectin are present in the specimen, when the liquid surface continues to migrate to the quality control area where goat anti-mouse IgG antibodies are fixed, a red strip will definitely appear in the quality control area. If no strip appears in the quality control area, it indicates that the test strip is invalid and the T-line result interpretation is invalid. When red strips appear in the test areas T1 and T2, it indicates a positive result, indicating that the chorion and decidua as well as the chorion and amnion of the subject are separated, and premature birth is about to occur. When only T2 appears in the test area, it indicates a positive result, indicating that the subject has premature rupture of membranes and is at risk of premature birth. When there are no red strips in the test areas T1 and T2, it indicates a negative result, indicating that the sample does not contain insulin-like growth factor binding protein-1 and fetal fibronectin or their content is below the detection limit, indicating that the risk of premature rupture of membranes or premature birth is low.
[0049] According to the test results of the present invention, it is shown that the insulin-like growth factor binding protein-1 and fetal fibronectin dual detection system provided by the present invention has high specificity, strong repeatability, high accuracy and long-term stability. Combined with the test results of the comparative example, it is shown that the treatment solution A and the treatment solution B provided by the present invention play an important role in improving the detection performance, and the components of the treatment solution B have a synergistic effect. DETAILED DESCRIPTION
[0050] The present invention will be further described in detail below in conjunction with specific examples. The following examples are not intended to limit the present invention, but are only intended to illustrate the present invention. The experimental methods used in the following examples are generally conventional, unless otherwise specified, and the materials, reagents, etc. used in the following examples are commercially available, unless otherwise specified.
[0051] Example 1 Preparation of a dual detection system for insulin-like growth factor binding protein-1 and fetal fibronectin
[0052] 1.1 Sample pad
[0053] The glass cellulose membrane was immersed in treatment solution A for 10 min and dried at 40°C for later use.
[0054] The formula of treatment solution A: 20 mM PBS buffer, 2% m / V PEG6000, 1% m / V Tween-20, 2% m / V sodium citrate, 4% m / V trehalose, 3% m / V BSA, 0.3% m / V PC-950, pH 8.
[0055] 1.2 Immunocolloidal gold pad
[0056] The glass cellulose membrane was immersed in treatment solution B for 7 minutes and dried at 40°C for later use.
[0057] The formula of treatment solution B: 5 mM PBS buffer, 0.1% m / V PEG6000, 0.5% m / V Tween-20, 1% m / V KCl, 2% m / V trehalose, 1.5% m / V mannitol, 1% m / V BSA, 0.1% m / V PC-950, pH 7.
[0058] 1.2.1 Preparation of gold-labeled antibody solution of insulin-like growth factor binding protein-1 antibody 1:
[0059] (1) Heat 1L of purified water to boiling, add 40mL of 1% m / v HAuCl4, and then quickly add 30mL of 2% m / v sodium citrate. Continue heating and stirring for 8 minutes. After cooling, obtain a colloidal gold solution.
[0060] (2) Take 10 mL of colloidal gold solution, add 100 μL of 0.1 M K2CO3 solution, mix well and set aside.
[0061] (3) Slowly add insulin-like growth factor binding protein-1 antibody 1 at a final concentration of 20 μg / mL, stir evenly, and let stand for 20 minutes.
[0062] (4) Add 100uL of BSA (final concentration of 10% m / V), mix well, and let stand for 5 minutes.
[0063] (5) After standing, centrifuge at 4-30°C (20°C in this embodiment) and 10,000 r / min for 10-20 min (15 min in this embodiment), take the precipitate, add the gold-labeled antibody re-solution (30 mM NaCl + 0.15% m / V BSA) and resuspend to obtain the gold-labeled antibody solution of insulin-like growth factor binding protein-1 antibody 1.
[0064] 1.2.2 Preparation of gold-labeled antibody solution of fetal fibronectin antibody a
[0065] (1) Heat 1L of purified water to boiling, add 40mL of 1% m / v HAuCl4, and then quickly add 30mL of 2% m / v sodium citrate. Continue heating and stirring for 8 minutes. After cooling, obtain a colloidal gold solution.
[0066] (2) Take 10 mL of colloidal gold solution, add 100 μL of 0.1 M K2CO3 solution, mix well and set aside.
[0067] (3) Slowly add fetal fibronectin antibody a at a final concentration of 20 μg / mL, stir evenly, and let stand for 20 minutes.
[0068] (4) Add 100uL of BSA (final concentration of 10% m / V), mix well, and let stand for 5 minutes.
[0069] (5) After standing, centrifuge at 4-30°C (20°C in this embodiment) and 10,000 r / min for 10-20 min (15 min in this embodiment), take the precipitate, add the gold-labeled antibody re-solution (30 mM NaCl + 0.15% m / V BSA) and resuspend to obtain the gold-labeled antibody solution of insulin-like growth factor binding protein-1 antibody 1.
[0070] 1.3 Nitrocellulose membrane
[0071] The test line and quality control line were coated on the nitrocellulose membrane (NC membrane), where the T1 test line was coated with insulin-like growth factor binding protein-1 antibody 2; the T2 test line was coated with fetal fibronectin antibody b; the quality control line was coated with goat anti-mouse IgG antibody. The T1 and T2 test lines were coated at a concentration of 0.5 mg / mL, and the C line was coated at a concentration of 0.7 mg / mL.
[0072] 1.4 Assembly of the dual detection system for insulin-like growth factor binding protein-1 and fetal fibronectin
[0073] Assemble them on the bottom plate in the order of sample pad - immune colloidal gold pad - nitrocellulose membrane - absorbent paper.
[0074] Example 2 Preparation of a dual detection system for insulin-like growth factor binding protein-1 and fetal fibronectin
[0075] The only difference from Example 1 is the treatment liquid A and the treatment liquid B, and the rest is the same as Example 1.
[0076] The formula of treatment solution A: 10 mM PBS buffer, 5% m / V PEG6000, 2% m / V Tween-20, 1% m / V sodium citrate, 2% m / V trehalose, 5% m / V BSA, 0.5% m / V PC-950, pH 7.
[0077] The formula of treatment solution B: 10 mM PBS buffer, 0.3% m / V PEG6000, 0.1% m / V Tween-20, 3% m / V KCl, 5% m / V trehalose, 0.5% m / V mannitol, 2% m / V BSA, 0.4% m / V PC-950, pH 7.8.
[0078] Comparative Example
[0079] Comparative Examples 1-5 were set up according to Example 1, and the comparative settings are shown in Table 1.
[0080] Table 1
[0081]
[0082] Experimental example
[0083] 1. Specificity determination of the dual detection system of insulin-like growth factor binding protein-1 and fetal fibronectin
[0084] The dual detection system of insulin-like growth factor binding protein-1 and fetal fibronectin in Examples 1-2 and Comparative Examples 1-5 respectively detects mixed solutions Q1-Q10 (concentrations shown in Table 2) containing insulin-like growth factor binding protein-1 and fetal fibronectin, and each concentration is tested 5 times, and the test time is 10 minutes. The qualitative detection of insulin-like growth factor binding protein-1 is positive (concentration ≥ 25ng / mL) and the test result is negative (<25ng / mL), and the qualitative detection of fetal fibronectin is negative (concentration <50ng / mL), and the test result is positive (concentration ≥50ng / mL). The components of the diluent used are: 0.01M disodium hydrogen phosphate, 0.01M sodium dihydrogen phosphate, 1%wt sodium chloride and 0.02%wt sodium azide, and the pH value is 8.0. The results of Examples 1-2 and Comparative Examples 1-5 are shown in Tables 3-4.
[0085] Table 2
[0086]
[0087] Table 3
[0088]
[0089] Table 4
[0090]
[0091] The results in Table 3-4 show that the dual detection system prepared in Examples 1-2 of the present invention has good specificity in detecting insulin-like growth factor binding protein-1 and fetal fibronectin, and its positive and negative coincidence rates both reach 100%, which is significantly better than Comparative Examples 1-4. Comparing the results of the examples with those of the comparative examples, it can be seen that the treatment solution A and treatment solution B provided by the present invention can significantly improve the specificity of the detection, and the results of Example 1 and Comparative Examples 3-5 show that trehalose and mannitol in the treatment solution play a synergistic role in improving the specificity of the detection.
[0092] 2. Repeatability test of the dual detection system of insulin-like growth factor binding protein-1 and fetal fibronectin
[0093] The insulin-like growth factor binding protein-1 and fetal fibronectin dual detection systems of Examples 1-2 and Comparative Examples 1-5 were used to detect Q5, Q6, and Q9, respectively. Each concentration was tested 10 times. The test results are shown in Tables 5-6.
[0094] Table 5
[0095]
[0096] Table 6
[0097]
[0098] The results in Tables 5-6 show that the dual detection system prepared in Examples 1-2 of the present invention also has high repeatability in detecting insulin-like growth factor binding protein-1 and fetal fibronectin, and is also significantly better than Comparative Examples 1-4. Compared with the comparative examples, the examples still prove that the treatment solution A and treatment solution B provided by the present invention can effectively improve the repeatability of the detection, wherein the trehalose and mannitol in treatment solution B have a synergistic effect in improving the repeatability.
[0099] 3. Long-term stability test of the dual detection system of insulin-like growth factor binding protein-1 and fetal fibronectin
[0100] The insulin-like growth factor binding protein-1 and fetal fibronectin dual detection systems of Examples 1-2 and Comparative Examples 1-5 were subjected to accelerated destruction at 50°C for 28 days, and Q5, Q6, and Q9 were detected using the insulin-like growth factor binding protein-1 and fetal fibronectin dual detection systems of Examples 1-2 on days 0, 15, and 28, respectively. The detection was repeated 5 times for each concentration, and the total compliance rate is shown in Table 7.
[0101] Table 7
[0102]
[0103] The results in Table 7 show that the dual detection system prepared in Example 1-2 of the present invention has good long-term stability, no false positive or false negative, and is suitable for production. However, the stability of Comparative Example 1-5 decreased significantly after 15 days, and no positive results were detected in the detection of Q5 and Q6 (positive samples) on the 28th day of accelerated destruction, but it has long-term stability in the detection of Q9 (negative sample).
[0104] 4. Clinical sample verification
[0105] 200 clinical samples were selected, of which 50 were premature group, 50 were premature rupture of membrane group, and 100 were normal group (diagnostic criteria for premature rupture of membrane group: judging by observing the outflow of amniotic fluid, checking the properties of the liquid, testing the acidity and alkalinity of the liquid, observing the condition of the cervical os, and ultrasound examination; diagnostic criteria for premature group: monitoring the change of cervical length, the presence of cervical glandular area, observing regular uterine contraction, cervical dilation, cervical receptivity, etc. by ultrasound; the normal group was the group without premature rupture of membrane and premature birth). The insulin-like growth factor binding protein-1 and fetal fibronectin dual detection system of Examples 1-2 and Comparative Examples 1-5 and Comparative Example 6 (commercially available reagent: insulin-like growth factor binding protein-1 / fetal fibronectin detection kit (colloidal gold method), Wuxi Bohuisi Biomedicine Technology Co., Ltd., registration certificate number: Su Xie Zhuzhu 20172401814) were used to detect clinical samples respectively. The test results are shown in Table 8. When red stripes appear in T1 and T2, it indicates that premature birth is about to occur; when a red stripe appears only in T2 in the test area, it indicates premature rupture of membranes.
[0106] Table 8
[0107]
[0108] Sensitivity = number of positive tests / (number of positive tests + number of false negative tests); specificity = number of negative tests / (number of negative tests + number of false positive tests),
[0109] The detection sensitivity of Example 1 is: (49+50) / (50+50)×100%=99%; the specificity is: 100 / 100×100%=100%.
[0110] The detection sensitivity of Example 2 is: (48+49) / (50+50)×100%=97%; the specificity is: 100 / 100×100%=100%.
[0111] The detection sensitivity of comparative example 1 is: (33+36) / (50+50)×100%=69%; the specificity is: 89 / 100×100%=89%.
[0112] The detection sensitivity of Comparative Example 2 is: (24+21) / (50+50)×100%=45%; the specificity is: 73 / 100×100%=73%.
[0113] The detection sensitivity of Comparative Example 3 is: (28+35) / (50+50)×100%=63%; the specificity is: 80 / 100×100%=80%.
[0114] The detection sensitivity of Comparative Example 4 is: (31+37) / (50+50)×100%=68%; and the specificity is: 84 / 100×100%=84%.
[0115] The detection sensitivity of Comparative Example 5 is: (25+30) / (50+50)×100%=55%; the specificity is: 87 / 100×100%=87%.
[0116] The detection sensitivity of Comparative Example 6 is: (41+42) / (50+50)×100%=55%; and the specificity is: 91 / 100×100%=91%.
[0117] The above results show that the sensitivity of the dual detection system of insulin-like growth factor binding protein-1 and fetal fibronectin in Examples 1-2 of the present invention is significantly higher than that in Comparative Examples 1-5, indicating that the treatment liquid A and treatment liquid B provided in the embodiments of the present invention significantly improve the detection performance of the detection system. And compared with Comparative Example 6, it is shown that the dual detection system of the present invention also has significant advantages over commercially available products.
Claims
1. A dual detection reagent strip for insulin-like growth factor binding protein-1 and fetal fibronectin, characterized in that: Includes sample pad, immunocolloidal gold pad, nitrocellulose membrane and absorbent paper; The sample pad is treated with treatment solution A, the formula of the treatment solution A is: 10-20mM PBS buffer, 2%-5%m / V PEG6000, 1%-2%m / V Tween-20, 1%-2%m / V sodium citrate, 2%-4%m / V trehalose, 3%-5%m / V BSA, 0.3%-0.5%m / V PC-950, pH 7-8; The immunocolloidal gold pad is treated with treatment solution B, wherein the treatment solution B has the following formula: 5-10 mM PBS buffer, 0.1%-0.3% m / V PEG6000, 0.1%-0.5% m / V Tween-20, 1%-3% m / V KCl, 2%-5% m / V trehalose, 0.5%-1.5% m / V mannitol, 1%-2% m / V BSA, 0.1%-0.4% m / V PC-950, pH 7-7.8; The sample pad and immune colloidal gold pad are made of glass cellulose membrane; The immunocolloidal gold pad is sprayed with a mixed solution of gold-labeled antibodies; The gold-labeled antibody mixed solution includes a gold-labeled antibody solution of insulin-like growth factor binding protein-1 antibody 1 and a gold-labeled antibody solution of fetal fibronectin antibody a; The nitrocellulose membrane is coated with the T1 detection line and the T2 detection line; The T1 detection line is coated with insulin-like growth factor binding protein-1 antibody 2; the T2 detection line is coated with fetal fibronectin antibody b.
2. A method for preparing the insulin-like growth factor binding protein-1 and fetal fibronectin dual detection reagent strip according to claim 1, characterized in that: The method comprises the following steps: S1. Preparation of sample pad: immerse the glass cellulose membrane in the treatment solution A, and dry it for later use; S2. Preparation of immunocolloidal gold pad: soak the glass cellulose membrane in the treatment solution B, dry it, spray it with the gold-labeled antibody mixed solution, dry it again and set it aside; S3. Preparation of nitrocellulose membrane: coating the nitrocellulose membrane with T1 detection line, T2 detection line and quality control line; S4. Assembly of reagent strips: Assemble in the order of sample pad - immunocolloidal gold pad - nitrocellulose membrane - absorbent paper.
3. The method according to claim 2, characterized in that The quality control line described in step S3 is coated with IgG antibody.
4. The method according to claim 3, characterized in that The IgG antibody is goat anti-mouse IgG.
5. Use of the insulin-like growth factor binding protein-1 and fetal fibronectin dual detection reagent strip according to claim 1 or the method according to any one of claims 2 to 4 in the preparation of a kit for the dual detection of insulin-like growth factor binding protein-1 and fetal fibronectin.
6. A kit for dual detection of insulin-like growth factor binding protein-1 and fetal fibronectin, characterized in that: The kit comprises the insulin-like growth factor binding protein-1 and fetal fibronectin double detection reagent strip according to any one of claim 1.
7. The kit according to claim 6, characterized in that Also included are sample preservation reagents.
8. The kit according to claim 7, characterized in that The sample is cervical secretion or vaginal secretion.
